These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

51 related articles for article (PubMed ID: 26287921)

  • 21. Substrate inhibition kinetic model for West Nile virus NS2B-NS3 protease.
    Tomlinson SM; Watowich SJ
    Biochemistry; 2008 Nov; 47(45):11763-70. PubMed ID: 18855422
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IRES mediated expression of viral 3C protease for enhancing the yield of FMDV empty capsids using baculovirus system.
    Vivek Srinivas VM; Basagoudanavar SH; Hosamani M
    Biologicals; 2016 Mar; 44(2):64-8. PubMed ID: 26775685
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of hepatitis A virus non-structural protein 2B and its release by the major virus protease 3C.
    Gosert R; Cassinotti P; Siegl G; Weitz M
    J Gen Virol; 1996 Feb; 77 ( Pt 2 )():247-55. PubMed ID: 8627228
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimization of a Stable Linker Involved DEVD Peptide-Doxorubicin Conjugate That Is Activated upon Radiation-Induced Caspase-3-Mediated Apoptosis.
    Chung SW; Lee BS; Choi Ju; Kim SW; Kim IS; Kim SY; Byun Y
    J Med Chem; 2015 Aug; 58(16):6435-47. PubMed ID: 26263187
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeted prodrug approaches for hormone refractory prostate cancer.
    Aloysius H; Hu L
    Med Res Rev; 2015 May; 35(3):554-85. PubMed ID: 25529338
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis and evaluation of nitroheterocyclic carbamate prodrugs for use with nitroreductase-mediated gene-directed enzyme prodrug therapy.
    Hay MP; Anderson RF; Ferry DM; Wilson WR; Denny WA
    J Med Chem; 2003 Dec; 46(25):5533-45. PubMed ID: 14640560
    [TBL] [Abstract][Full Text] [Related]  

  • 27. What should be considered on design of a colon-specific prodrug?
    Jung Y; Kim YM
    Expert Opin Drug Deliv; 2010 Feb; 7(2):245-58. PubMed ID: 20095945
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Virus-directed enzyme prodrug therapy using CB1954.
    Grove JI; Searle PF; Weedon SJ; Green NK; McNeish IA; Kerr DJ
    Anticancer Drug Des; 1999 Dec; 14(6):461-72. PubMed ID: 10834268
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics, metabolism, and excretion of the intestinal peptide transporter 1 (SLC15A1)-targeted prodrug (1S,2S,5R,6S)-2-[(2'S)-(2-amino)propionyl]aminobicyclo[3.1.0.]hexen-2,6-dicarboxylic acid (LY544344) in rats and dogs: assessment of first-pass bioactivation and dose linearity.
    Perkins EJ; Abraham T
    Drug Metab Dispos; 2007 Oct; 35(10):1903-9. PubMed ID: 17646281
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Probing the substrate specificity of the dengue virus type 2 NS3 serine protease by using internally quenched fluorescent peptides.
    Niyomrattanakit P; Yahorava S; Mutule I; Mutulis F; Petrovska R; Prusis P; Katzenmeier G; Wikberg JE
    Biochem J; 2006 Jul; 397(1):203-11. PubMed ID: 16489931
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis of a novel legumain-cleavable colchicine prodrug with cell-specific toxicity.
    Smith RL; Åstrand OA; Nguyen LM; Elvestrand T; Hagelin G; Solberg R; Johansen HT; Rongved P
    Bioorg Med Chem; 2014 Jul; 22(13):3309-15. PubMed ID: 24842619
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimization of digestion parameters for protein quantification.
    Norrgran J; Williams TL; Woolfitt AR; Solano MI; Pirkle JL; Barr JR
    Anal Biochem; 2009 Oct; 393(1):48-55. PubMed ID: 19501563
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The SENECA study: potentials and problems in assessing dietary changes over time.
    van Staveren WA; Burema J; de Groot CP
    Int J Sports Med; 1997 Jul; 18 Suppl 3():S195-9. PubMed ID: 9272848
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selective inhibition of dipeptidyl peptidase 4 by targeting a substrate-specific secondary binding site.
    Kühn-Wache K; Bär JW; Hoffmann T; Wolf R; Rahfeld JU; Demuth HU
    Biol Chem; 2011 Mar; 392(3):223-31. PubMed ID: 21284559
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Substrate-Competitive Activity-Based Profiling of Ester Prodrug Activating Enzymes.
    Xu H; Majmudar JD; Davda D; Ghanakota P; Kim KH; Carlson HA; Showalter HD; Martin BR; Amidon GL
    Mol Pharm; 2015 Sep; 12(9):3399-407. PubMed ID: 26262434
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline.
    Rudin CM; Ismaila N; Hann CL; Malhotra N; Movsas B; Norris K; Pietanza MC; Ramalingam SS; Turrisi AT; Giaccone G
    J Clin Oncol; 2015 Dec; 33(34):4106-11. PubMed ID: 26351333
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correction: Seneca Valley Virus 3Cpro Substrate Optimization Yields Efficient Substrates for use in Peptide-Prodrug Therapy.
    Miles LA; Brennen WN; Rudin CM; Poirier JT
    PLoS One; 2015; 10(8):e0136480. PubMed ID: 26287921
    [No Abstract]   [Full Text] [Related]  

  • 38. Seneca Valley Virus 3Cpro Substrate Optimization Yields Efficient Substrates for Use in Peptide-Prodrug Therapy.
    Miles LA; Brennen WN; Rudin CM; Poirier JT
    PLoS One; 2015; 10(6):e0129103. PubMed ID: 26069962
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Correction to: Intercellular transmission of Seneca Valley virus mediated by exosomes.
    Xu G; Xu S; Shi X; Shen C; Hao J; Yan M; Zhang D; Zhu Z; Zhang K; Zheng H; Liu X
    Vet Res; 2020 Aug; 51(1):103. PubMed ID: 32811541
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Specificity of the polioviral proteinase 3C towards genetically engineered cleavage sites in the viral capsid.
    Mirzayan C; Ingraham R; Wimmer E
    J Gen Virol; 1991 May; 72 ( Pt 5)():1159-63. PubMed ID: 1851816
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.